


PHARMACEUTICAL 2020

Assertio Therapeutics Inc Rank 171 of 362





PHARMACEUTICAL 2020

Assertio Therapeutics Inc Rank 171 of 362

The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 183% points. The greatest weakness of Assertio Therapeutics Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 197% points.

The company's Economic Capital Ratio, given in the ranking table, is -164%, being 139% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	103,951
Cost of Goods Sold	0
Intangible Assets	400,535
Liabilities, Current	184,553
Liabilities, Non-Current	13,233
Other Assets	19,187
Other Compr. Net Income	0
Other Expenses	299,660
Other Liabilities	271,426
Other Net Income	-28,056
Property and Equipment	3,497
Research and Development	10,106
Revenues	229,504
Selling, General and Administrative Expense	108,866

Output Variable	Value in 1000 USD
Assets	527,170
Liabilities	469,212
Expenses	418,632
Stockholders Equity	57,958
Net Income	-217,184
Comprehensive Net Income	-217,184
Economic Capital Ratio	-164%